CXCL13 and astrocytoma (excluding glioblastoma): The goal of this study is to substantiate the clinicopathological significances for CXCL13 and M2 patterns (CD163+) in astrocytoma and to compare the potential utility of CXCL13 and CD163 as diagnostic biomarkers, alone and in combination, which discriminates between the different grades of astrocytoma (grades II, III, IV).